Key PointsTherapy–mediated BCMA expression loss after belantamab or anti-BCMA chimeric antigen receptor T cells underlies teclistamab failure in RRMM.Low/u
Join us at San Antonio Breast Cancer Symposium (SABCS) 2024 on December 10 &12 for the latest in breast cancer treatment. Register today to earn…
Multiple myeloma, a plasma-cell neoplasm characterized by skeletal destruction, renal failure, anemia, and hypercalcemia, remains incurable. However, recent advances in its treatment, in particular…
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical…
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes…
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in…
Program: Oral and Poster Abstracts Type: Oral Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel…
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics &…
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy,…
Background: Clonal Hematopoiesis (CH) is a well established confounder in next-generation sequencing (NGS)-based liquid biopsy cancer diagnostics. Misclassification of CH variants as tumor variants can…
Purpose To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient’s tumor with the PFS for the…
